Released Nov 1, 2018, after the close
10-Q filed Nov 6, 2018, 37 days after period end · 0001162194-18-000104
Q3 2018 · 10-Q
Revenue$28.96M$28.96M +17.0% vs Q3 2017+9.6% vs Q2 2018
Net Income-$14.75M-$14.75M N/M vs Q3 2017N/M vs Q2 2018
EPS Diluted-$0.38-$0.38 N/M vs Q3 2017N/M vs Q2 2018
Gross Profit$15,822,000—
Operating Income-$11,628,000N/M
Operating Cash Flowderived-$4,064,000N/M
Free Cash Flowderived-$4,262,000N/M
Margins · derived
Gross margin54.6%
Operating margin-40.1%+22.9 pt vs Q3 2017
Net margin-50.9%+13.5 pt vs Q3 2017
What the release said
The release
Same quarter
| Metric | Q3 2018 | Q3 2017 | Q3 2016 | Q3 2015 |
|---|---|---|---|---|
| Revenue | $28.96M | $24.75M | $22.19M | $28.64M |
| Net Income | -$14.75M | -$15.94M | -$19.79M | -$9.27M |
| EPS Diluted | -$0.38 | -$0.46 | -$0.68 | -$0.32 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Standard Biotools Inc. · CIK 1162194 · Engraved from SEC EDGAR